|
The selection and the precise choice of MiRNA
> Introduction
 Human central nervous system tumors are mostly gliomas (50%), comprising generally of two sub categories: glioblastomas and oligodendrogliomas. These tumors, which are the leading cause of morbidity and mortality of patients with glial tumours represent a significant public health problem, with a median survival of seven years for oligodendrogliomas, and a comparable figure of only one year for glioblastomas after treatment.There is thus a great need to develop a diagnostic method capable of reliably and consistently detecting and correctly diagnosing early glial tumors perfectly.
The only current means of diagnosis relies on biopsies; a process known to be inconsistent and open to errors in terms of interpretation (two different experts may offer different diagnoses on the same sample). This innovative technology has no current equivalent, and is a solution to this problem of diagnosis. It utilizes the identification and use of microRNA biomarkers (known to play a key role in breakdowns in cellular processes, including glial tumors ) to ensure a simple, sensitive, consistant and accurate diagnosis.
> Principles of the technology
The selection and the precise choice of these MiRNA have been carried out by molecular analysis based on blood and tissue samples, necessitating the following steps:
1- LMicroRNA (RNA non coding for around 22 bases) have been extracted from tumoral tissue and submitted to quality control checks
2- The microRNA are administrated by methods based on hybridisation (DNA chips) on PCR (RT-qPCR) or via sequencing (next generation sequencing)
3- Expression profiles of several microRNA are used according to tumor type
4- The analysis of tumor type is made by comparison to reference values (reference grid)
In the end, the miRNA most evident in the diagnosis are selected and held back for use in the diagnosis and specification of glial tumors
> Main Benefits
 • Relative stability of microRNAs in relation to messenger RNA,
• Very high sensitivity wit regards to detection (PCR amplification possibilities),
• Speed and consistency of diagnosis
• Reliability, without requiring specific expertise,
• Multiparameter-based diagnosisusing several microRNA biomarkers,
• simultaneous detection of biomarkers (DNA hybridization on microarrays, RTqPCR, high throughput sequencing)
• Mature-technology already proven at a clinical level
> Target Market
- Cancer diagnosis (tumors in humans)
- Theranostics
> Commercial Opportunity
We are currently looking for industrial partners to collaborate on the development of this exciting technology
> Companies distributing diagnostic kits
> Pharma co’s interested in developing companion tests
> CRO (Stratification of patients in pharmacological studies)
> Intellectual Property
Three patents protect this technology: FR 09 58737 (08/12/2009) ; FR 10/60278 (08/12/2010) ; FR 10/60279 (08/12/2010) - From: UJF et CHU Grenoble
> Contact
Carole Speziani
Tel. +33 (0)4 56 00 60 43
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
